Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond (pages 1245–1252)
Lisa Lima, Leon Bernal-Mizrachi, Debra Saxe, Karen P. Mann, Mourad Tighiouart, Martha Arellano, Leonard Heffner, Morgan McLemore, Amelia Langston, Elliott Winton and Hanna Jean Khoury
Article first published online: 2 NOV 2010 | DOI: 10.1002/cncr.25678
In this article, the authors analyzed simultaneously obtained bone marrow cytogenetics (CTG)/ fluorescence in situ hybridization (FISH)/polymerase chain reaction (PCR) and blood FISH/PCR in 70 patients with all phases of chronic myeloid leukemia who were treated with modern therapies. To the authors' knowledge, the current study is the first to provide information regarding correlations obtained on simultaneously obtained BM and blood FISH and PCR and marrow CTG simultaneous FISH, PCR, and CTG; and provides correlations in patients treated with imatinib, dasatinib, nilotinib, bosutinib, and homoharringtonine.